SRT1720 – Kodiac biolabs

Plain-language summaryIntrigue 50 / 100

SRT1720 is the structural ancestor of SRT2104, the original imidazothiazole SIRT1 activator from Sirtris (now GSK), about 1000 times more potent than resveratrol at SIRT1. Mouse studies showed lifespan extension in diet-induced obese mice and improvement in age-related metabolic and pathological markers. SRT2104 was later derived from this scaffold with better human pharmacokinetic properties. Whether SIRT1 activation is the actual mechanism for the in vivo effects has been disputed for over a decade, with some labs unable to reproduce the activation chemistry in cell-free assays. Important historically as the proof-of-concept compound for the sirtuin pharmacology program, but limited human relevance. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundNiche research probe

40/100

Superseded sirtuin probe with real mouse pharmacology but no translational runway

Look, SRT1720 occupies a specific and somewhat awkward position in the sirtuin literature. It was the headline compound out of Sirtris Pharmaceuticals before GlaxoSmithKline acquired the outfit in 2008, and for a few years it was the sharpest tool available for interrogating SIRT1 biology in rodents. The roughly 1000-fold potency advantage over resveratrol as a SIRT1 activator was real, the mouse lifespan extension data in diet-induced obese animals published by Milne and colleagues held up on replication, and the metabolic phenotype work was genuinely interesting. We think that body of rodent data is still the compound’s main selling point in 2025.

Here’s the thing, though. The mechanism controversy matters. In 2010, Pacholec et al. published in the Journal of Biological Chemistry arguing that SRT1720 and related compounds were activating SIRT1 only in the context of fluorescent substrate assays, not with natural peptide substrates, implying the whole activation story was a biochemical artifact. That paper hit the field hard. The 2013 Hubbard et al. work in Science partially rehabilitated the allosteric mechanism by showing activation does occur with certain natural substrates containing hydrophobic motifs adjacent to the acetyl-lysine, but the qualification is load-bearing: not all SIRT1 substrates respond equally, and the interpretation of older studies using this compound gets complicated fast. Serious investigators working in this area now have to navigate that literature carefully.

The differentiation story is equally constrained. SRT2104 was explicitly developed as the human-ready successor, with improved metabolic stability and PK that actually support clinical dosing. SRT2104 has been in human trials (inflammation, muscle atrophy, Type 2 diabetes endpoints). SRT1720 has not. That division of labor is by design, and it means SRT1720 is basically a rodent-only probe at this point. If your research program lives in mouse models and you’re specifically asking questions about SIRT1-dependent metabolic or longevity phenotypes, the established pharmacology is genuinely useful and the plasma half-life around 8 to 10 hours in rodents is well characterized. Outside of that narrow use case, you’re better served by SRT2104 for anything translational.

What we dont see here is a strong argument for prioritizing SRT1720 over other tools in sirtuin biology. EX-527 handles the inhibitor side cleanly. SRT2104 handles the human-relevant activation angle. SRT1720 sits in the middle as a historically important compound that still earns its place on the shelf for specific rodent studies, but that’s a qualified endorsement. The mechanism overhead, the translational ceiling, and the fact that theres a better successor compound all push this toward the lower tier of the library despite the real and replicated mouse data underpinning it.

Novelty: 35
Mechanism promise: 52
In-category differentiation: 30
Evidence quality: 42
Translational signal: 28
Research bench value: 60

Rationale SRT1720 scores as a niche probe because its primary research value is now confined to rodent SIRT1 pharmacology studies where its established mouse PK is an asset; the compound was deliberately retired as a translational candidate when Sirtris developed SRT2104 with better human pharmacokinetics, and the 2010 Pacholec et al. mechanism challenge still casts interpretive overhead on legacy studies even though the allosteric story was partially rehabilitated by Hubbard et al. in 2013.

Selective SIRT1 activator

An imidazothiazole SIRT1 activator; the structural lineage compound from which SRT2104 was developed.

Abstract

SRT1720 (CAS 925434-55-5; molecular formula C22H19N5OS2; molecular weight 433.55) is an imidazothiazole SIRT1 activator developed at Sirtris Pharmaceuticals as a potent (approximately 1000-fold over resveratrol) and selective sirtuin 1 activator. Mechanism is allosteric SIRT1 activation comparable to SRT2104. Mouse studies demonstrated lifespan extension in diet-induced obese mice, improved metabolic parameters, and reduced age-related pathology. The compound was the foundation for the broader Sirtris drug discovery program; SRT2104 was developed as a more drug-like successor with better human pharmacokinetics. SRT1720 is used preferentially in academic research where the established mouse pharmacology is valuable. Plasma half-life is approximately 8 to 10 hours.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-302Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.